The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11110 malaria professionals are enjoying the free benefits of MalariaWorld today


Not Open Access | Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial

November 25, 2021 - 12:35 -- NOT Open Access
Sissoko MS, Healy SA, Duffy PE, et al.
Lancet Infect Dis. 2021 Nov 18:S1473-3099(21)00332-7

WHO recently approved a partially effective vaccine that reduces clinical malaria in children, but increased vaccine activity is required to pursue malaria elimination. A phase 1 clinical trial was done in Mali, west Africa, to assess the safety, immunogenicity, and protective efficacy of a three-dose regimen of Plasmodium falciparum sporozoite (PfSPZ) Vaccine (a metabolically active, non-replicating, whole malaria sporozoite vaccine) against homologous controlled human malaria infection (CHMI) and natural P falciparum infection.

The provider’s checklist to improve pregnant women coverage by intermittent preventive malaria treatment in Mali: a pilot implementation study

October 29, 2021 - 14:09 -- Open Access
Issa Doumbia, Fomba Seydou, Koné Diakalia and Issam Bennis
Malaria Journal 2021 20:402, 16 October 2021

Intermittent preventive treatment of malaria in pregnancy (IPTp) is a comprehensive treatment protocol of anti-malarial drugs administered to pregnant women to prevent malaria, started at the fourth pregnancy month, with at least three doses of sulfadoxine–pyrimethamine (SP), taken as directly observed treatment (DOT) every 30 days at intervals until childbirth, in combination with other preventive measures. This paper introduces feasibility and adoption concepts as implementation research outcomes (IRO), allowing after a defined intervention, to assess the coverage improvement by IPTp for women attending a reference district hospital in Mali. Specifically, the purpose is to evaluate the feasibility of a reminder tool (provider checklist) to enhance pregnant women’s adoption of information about IPTp-SP uptake as immediate and sustained women practices.

Artemisinin-based combination therapy for uncomplicated Plasmodium falciparum malaria in Mali: a systematic review and meta-analysis

September 1, 2021 - 16:38 -- Open Access
Fatoumata O. Maiga, Mamadou Wele, Jeffrey G. Shaffer, et al.
Malaria Journal 2021 20:356, 30 August 2021

Artemisinin-based combination therapy (ACT) was deployed in 2005 as an alternative to chloroquine and is considered the most efficacious treatment currently available for uncomplicated falciparum malaria. While widespread artemisinin resistance has not been reported to date in Africa, recent studies have reported partial resistance in Rwanda. The purpose of this study is to provide a current systematic review and meta-analysis on ACT at Mali study sites, where falciparum malaria is highly endemic.

Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation

July 20, 2021 - 11:54 -- Open Access
Ventimiglia NT, Stucke EM, Travassos MA, et al.
Sci Rep. 2021 Jul 13;11(1):14401

Plasmodium falciparum erythrocyte membrane protein-1s (PfEMP1s), diverse malaria proteins expressed on the infected erythrocyte surface, play an important role in pathogenesis, mediating adhesion to host vascular endothelium. Antibodies to particular non-CD36-binding PfEMP1s are associated with protection against severe disease.

Antibody Levels to Plasmodium falciparum Erythrocyte Membrane Protein 1-DBLgamma11 and DBLdelta-1 Predict Reduction in Parasite Density

June 16, 2021 - 14:53 -- Open Access
Araj BN, Swihart B, Fried M, et al.
mSystems. 2021 Jun 15:e0034721

Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a variant surface antigen family expressed on infected red blood cells that plays a role in immune evasion and mediates adhesion to vascular endothelium. PfEMP1s are potential targets of protective antibodies as suggested by previous seroepidemiology studies. Here, we used previously reported proteomic analyses of PfEMP1s of clinical parasite isolates collected from Malian children to identify targets of immunity.

NOT Open Access | Plasmodium malariae and Plasmodium falciparum comparative susceptibility to antimalarial drugs in Mali

May 26, 2021 - 09:43 -- NOT Open Access
Dembele L, Aniweh Y, Djimde AA, et al.
J Antimicrob Chemother. 2021 May 22:dkab133

To evaluate Plasmodium malariae susceptibility to current and lead candidate antimalarial drugs.

Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015–2016

May 26, 2021 - 09:33 -- Open Access
Youssouf Diarra, Oumar Koné, Ousmane A. Koita, et al.
Malaria Journal 2021 20:235, 25 May 2021

The current first-line treatments for uncomplicated malaria recommended by the National Malaria Control Programme in Mali are artemether–lumefantrine (AL) and artesunate–amodiaquine (ASAQ). From 2015 to 2016, an in vivo study was carried out to assess the clinical and parasitological responses to AL and ASAQ in Sélingué, Mali.

Determinants of intermittent preventive treatment with sulfadoxine–pyrimethamine in pregnant women (IPTp-SP) in Mali, a household survey

May 26, 2021 - 09:22 -- Open Access
Oumar Sangho, Moctar Tounkara, Lillian Joyce Whiting-Collins, Madeleine Beebe, Peter J. Winch and Seydou Doumbia
Malaria Journal 2021 20:231, 22 May 2021

In malaria endemic regions, intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) is recommended for all pregnant women during prenatal consultation, from the fourth month of pregnancy up to the time of delivery. The Government of Mali is aiming for universal coverage of IPTp-SP. However, coverage is still low, estimated to be 18% for completion of three doses (IPTp-SP3). The objective of this study was to identify the factors that influence IPTp-SP adherence in the Health District of Sélingué, Mali.

NOT Open Access | Experimenting with co-development: A qualitative study of gene drive research for malaria control in Mali

May 5, 2021 - 10:16 -- NOT Open Access
Hartley S, Ledingham K, Owen R, Leonelli S, Diarra S, Diop S
Soc Sci Med. 2021 May;276:113850

We investigate how technology 'co-development' (between researchers, stakeholders and local communities) is framed in practice by those developing gene drive mosquitos for malaria eradication. Our case study focuses on UK and Mali-based researchers planning to undertake the first field trials in Mali of gene drive mosquitos for malaria control. While they and the wider gene drive research community are explicitly committed to the principle of co-development, how this is framed and practiced is not clear.

Malaria infection is common and associated with perinatal mortality and preterm delivery despite widespread use of chemoprevention in Mali: an observational study 2010 to 2014

April 14, 2021 - 08:22 -- Open Access
Mahamar A, Andemel N, Fried M, et al.
Clin Infect Dis. 2021 Apr 13:ciab301

In malaria-endemic areas, pregnant women and especially first-time mothers are more susceptible to Plasmodium falciparum. Malaria diagnosis is often missed during pregnancy, since many women with placental malaria remain asymptomatic or have submicroscopic parasitemia, masking the association between malaria and pregnancy outcomes Severe maternal anemia and low birthweight deliveries are well-established sequelae, but few studies have confirmed the relationship between malaria infection and severe outcomes like perinatal mortality in high transmission zones.


Subscribe to RSS - Mali